Seattle Genetics is at the forefront of treating cancer with targeted therapies. Its founder and CEO is Dr. Clay Siegall. He’s been proven to be a visionary in his approach to cancer treatment. He’s taken the company from a small startup to a major force in cancer treatment and research. Seattle Genetics has partnerships with major pharmaceutical firms such as Bayer and Pfizer among others. Their drug pipeline is currently over twenty indicating their strong research capabilities. Dr. Siegall believes that the old standards of treatment, notably chemotherapy, will be swept away by new, targeted therapies that will be more effective and have far fewer side effects.
Dr. Siegall believes in the power of medicine and technology to help overcome disease. He was first inspired by a relative’s struggle with chemotherapy and its particularly severe side effects. This person had almost died from the chemotherapy as opposed to cancer. From there was born a determination to make a difference in the realm of disease. He also craved the autonomy that his own endeavor would provide. Starting his own biotech company also enabled him to reap a greater share of the profits, more in line with his contributions.
Seattle Genetics derives a substantial income from selling their own proprietary drugs. They also earn money from production partnerships and licensing of unique technology and processes they’ve developed. The road to profitability was a long one, taking ten years from the IPO. Dr. Siegall credits his talented sales staff as essential to generating sales. They’re biotech-savvy and know the business fully. He credits old fashioned hard work for his success, citing passion and intensity.
Dr. Siegall’s education includes a B.S. in Zoology from the University of Maryland and a Ph.D. in Genetics from George Washington University. He’s an experienced fundraiser, helping secure funding for the IPO of Seattle Genetics. Prior to founding Seattle Genetics, he was working with Bristol-Myers Squibb Pharmaceutical Research Institute.
Dr. Siegall has written extensively appearing in over 70 publications and holds 15 patents. He also serves on three boards of directors including, Ultragenyx Pharmaceutical, Alder BioPharmaceuticals, and Washington Roundtable.